Soligenix Inc. (NASDAQ:SNGX) Short Interest Update

Soligenix Inc. (NASDAQ:SNGX) saw a significant increase in short interest in December. As of December 15th, there was short interest totaling 492,405 shares, an increase of 33.0% from the November 30th total of 370,215 shares. Approximately 5.0% of the company’s shares are short sold. Based on an average trading volume of 317,539 shares, the short-interest ratio is currently 1.6 days. Based on an average trading volume of 317,539 shares, the short-interest ratio is currently 1.6 days. Approximately 5.0% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Soligenix in a research note on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $6.00.

Soligenix Stock Performance

SNGX traded down $0.07 during trading on Tuesday, hitting $1.35. 189,932 shares of the stock were exchanged, compared to its average volume of 3,200,015. The firm has a 50 day simple moving average of $1.46 and a 200 day simple moving average of $1.87. The firm has a market cap of $13.57 million, a price-to-earnings ratio of -0.37 and a beta of 1.83. Soligenix has a 1 year low of $1.09 and a 1 year high of $6.23.

Soligenix (NASDAQ:SNGX) last released its quarterly earnings data on Friday, November 7th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.05. As a group, equities analysts anticipate that Soligenix will post -4.65 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Connective Capital Management LLC raised its stake in shares of Soligenix by 17.6% during the 2nd quarter. Connective Capital Management LLC now owns 119,481 shares of the biopharmaceutical company’s stock worth $157,000 after acquiring an additional 17,848 shares in the last quarter. Sabby Management LLC purchased a new position in Soligenix in the third quarter worth $94,000. Armistice Capital LLC purchased a new position in Soligenix in the third quarter worth $821,000. Virtu Financial LLC purchased a new stake in shares of Soligenix during the 3rd quarter valued at $59,000. Finally, Two Sigma Investments LP acquired a new stake in shares of Soligenix in the 3rd quarter worth $102,000. 3.60% of the stock is owned by institutional investors.

Soligenix Company Profile

Soligenix, Inc is a clinical‐stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small‐molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.

The company’s pipeline is organized into two core divisions.